Aridis Pharmaceuticals, Inc.
ARDS · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | -0.00 | 0.01 | 0.03 |
| FCF Yield | -25.72% | -54.74% | -41.89% | -39.99% |
| EV / EBITDA | -10.65 | 1.03 | -1.97 | -3.11 |
| Quality | ||||
| ROIC | 12.48% | -158.59% | 27.00% | 42.73% |
| Gross Margin | 100.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 11.84 | -0.36 | 0.59 | 1.34 |
| Growth | ||||
| Revenue 3-Year CAGR | 435.03% | 741.25% | -33.66% | -33.66% |
| Free Cash Flow Growth | 77.37% | -8.52% | 53.50% | -101.78% |
| Safety | ||||
| Net Debt / EBITDA | -5.93 | 0.46 | -0.43 | -0.17 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 111.58 | 1.37 | 0.00 | 0.00 |